SCHEDULE: Alyeska Investment Group Discloses 9.9% Stake in Marker Therapeutics

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, reported a 9.9% beneficial ownership stake in Marker Therapeutics, Inc., totaling 1,280,952 shares.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 1,280,952 shares of Marker Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of the total class of securities.
• The reporting persons hold shared voting power and shared dispositive power over all 1,280,952 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The reporting persons also hold warrants to purchase 937,500 shares and pre-funded warrants to purchase 604,950 shares.
• Per their terms, these warrants can only be exercised into shares that would constitute 9.99% of the total outstanding Common Stock immediately after exercise.
• As of September 30, 2025, the reporting persons could only exercise up to 1,280,952 shares under the warrant agreement due to this limitation.
• The percentage calculation assumes 12,938,910 outstanding shares of Common Stock, based on Marker Therapeutics' Form 10-Q filed on August 14, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or outlook. The presence of a significant institutional investor can be seen as a neutral to slightly positive signal.

Positives

• A significant institutional investor, Alyeska Investment Group, L.P., has disclosed a substantial 9.9% stake in Marker Therapeutics, Inc., which can be viewed as a vote of confidence in the company's future prospects.
• The acquisition of shares is stated to be in the ordinary course of business, indicating a strategic investment rather than an activist play.

Negatives

• No explicit negatives regarding Marker Therapeutics, Inc.'s operations or financial health are detailed in this ownership disclosure.

Risks

• No specific operational risks for Marker Therapeutics, Inc. are detailed in this ownership disclosure. The filing primarily concerns beneficial ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Marker Therapeutics, Inc.'s future operations or financial performance. It is solely an ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." Alyeska Investment Group, L.P. (signed by Jason Bragg, Chief Financial Officer), Alyeska Fund GP, LLC (signed by Jason Bragg, Chief Financial Officer), and Anand Parekh (signed by Anand Parekh).

Industry Context

This filing is an ownership disclosure, indicating a significant institutional investment in Marker Therapeutics, Inc., a company operating in the biotechnology sector. While it doesn't provide direct industry trends, it highlights continued investor interest in companies within this space.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Alyeska Investment Group may be viewed positively, potentially increasing investor confidence and market liquidity.
• Company Management: Awareness of a large institutional holder may influence strategic decisions or communication strategies.

Next Steps

• No specific future actions, events, or milestones for Marker Therapeutics, Inc. are mentioned in this ownership disclosure.

Key Dates

Keywords

Marker Therapeutics, Alyeska Investment Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Warrants, Biotechnology, Healthcare